JP2015504071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504071A5 JP2015504071A5 JP2014551304A JP2014551304A JP2015504071A5 JP 2015504071 A5 JP2015504071 A5 JP 2015504071A5 JP 2014551304 A JP2014551304 A JP 2014551304A JP 2014551304 A JP2014551304 A JP 2014551304A JP 2015504071 A5 JP2015504071 A5 JP 2015504071A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- group
- cell
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261582723P | 2012-01-03 | 2012-01-03 | |
| US61/582,723 | 2012-01-03 | ||
| PCT/US2013/020058 WO2013103658A1 (en) | 2012-01-03 | 2013-01-03 | Native and agonist ctl epitopes of the muc1 tumor antigen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504071A JP2015504071A (ja) | 2015-02-05 |
| JP2015504071A5 true JP2015504071A5 (https=) | 2016-02-25 |
| JP6523685B2 JP6523685B2 (ja) | 2019-06-05 |
Family
ID=47559756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551304A Active JP6523685B2 (ja) | 2012-01-03 | 2013-01-03 | Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10138271B2 (https=) |
| EP (1) | EP2800762B1 (https=) |
| JP (1) | JP6523685B2 (https=) |
| AU (1) | AU2013206896B2 (https=) |
| CA (1) | CA2860599C (https=) |
| DK (1) | DK2800762T3 (https=) |
| ES (1) | ES2664325T3 (https=) |
| WO (1) | WO2013103658A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| US8871247B2 (en) | 2007-02-19 | 2014-10-28 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| EP3060232B1 (en) * | 2013-10-23 | 2018-07-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| WO2017045691A1 (en) * | 2015-09-16 | 2017-03-23 | Herlev Hospital | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof |
| CA3036799C (en) | 2016-09-28 | 2025-05-13 | Bavarian Nordic A/S | COMPOSITIONS AND METHODS FOR IMPROVING THE STABILITY OF TRANSGENES IN POXVIRUSES |
| EP3542814B1 (en) * | 2018-03-21 | 2022-08-24 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| MX2021005560A (es) | 2018-11-20 | 2021-06-23 | Bavarian Nordic As | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). |
| CN114867491B (zh) | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| AU2022434346A1 (en) * | 2022-01-24 | 2024-07-25 | Cyron Therapeutics Co., Ltd. | Antibody specifically binding to muc-1 and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| IE912535A1 (en) | 1990-07-27 | 1992-01-29 | Res Dev Foundation | Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| ES2357960T3 (es) | 1997-05-08 | 2011-05-04 | Oncothyreon Inc. | Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos. |
| US20090004212A1 (en) * | 1997-12-30 | 2009-01-01 | Franz-Georg Hanisch | Tumour vaccines for MUC1-positive carcinomas |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| JP2003510094A (ja) * | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Ｍｕｃ−１由来のペプチド |
| EP1601333B1 (en) | 2003-02-20 | 2013-01-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US7696306B2 (en) | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| ES2476990T3 (es) | 2003-11-12 | 2014-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sistema para tratar y prevenir cáncer de mama |
| ES2623812T3 (es) | 2003-11-12 | 2017-07-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Vectores a medida para tratar y prevenir cáncer pancreático |
| JP5060134B2 (ja) * | 2003-12-12 | 2012-10-31 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ |
| JP2009544291A (ja) * | 2006-07-25 | 2009-12-17 | フォージー ヴァクシンズ ピーティーワイ エルーティーディー | ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| KR102049928B1 (ko) * | 2011-08-17 | 2019-11-28 | 글로브이뮨 | 효모-muc1 면역요법 조성물 및 그 용도 |
-
2013
- 2013-01-03 EP EP13700352.1A patent/EP2800762B1/en active Active
- 2013-01-03 WO PCT/US2013/020058 patent/WO2013103658A1/en not_active Ceased
- 2013-01-03 US US14/370,595 patent/US10138271B2/en active Active
- 2013-01-03 ES ES13700352.1T patent/ES2664325T3/es active Active
- 2013-01-03 JP JP2014551304A patent/JP6523685B2/ja active Active
- 2013-01-03 DK DK13700352.1T patent/DK2800762T3/en active
- 2013-01-03 CA CA2860599A patent/CA2860599C/en active Active
- 2013-01-03 AU AU2013206896A patent/AU2013206896B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504071A5 (https=) | ||
| CN103751771B (zh) | 免疫诱导剂 | |
| KR102874251B1 (ko) | 신생항원 및 이의 용도 | |
| TWI869347B (zh) | 新抗原及其用途 | |
| JP6558699B2 (ja) | 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン | |
| CN1805758B (zh) | 核酸和细胞疫苗的组分 | |
| RU2008114624A (ru) | Композиции и способы для лечения опухолей, презентирующих антигены сурвивина | |
| CN106029699A (zh) | Wt1抗原性多肽和含有该多肽的抗肿瘤剂 | |
| US20230190899A1 (en) | Immune inducer | |
| CN120983614A (zh) | 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物 | |
| KR20220110181A (ko) | 다중-도메인 단백질 백신 | |
| US20220331417A1 (en) | Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors | |
| JP2012504948A (ja) | ヒト上皮細胞の免疫賦活活性の増強剤としてのオンコスタチンｍ | |
| JP3876162B2 (ja) | 肝細胞癌の治療のための方法及び組成物 | |
| EP1074267B1 (en) | Induction of antigen-specific T cells by interferon | |
| CN108697757B (zh) | 免疫诱导剂 | |
| RU2733841C2 (ru) | Иммуноиндуцирующее средство | |
| JP7160462B2 (ja) | 免疫誘導剤 | |
| CA2993427C (en) | Immune inducer | |
| BR112018001542B1 (pt) | Iindutor de imunidade e uso do indutor de imunidade |